(Q40207173)

English

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

scientific article published on June 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

cervical intraepithelial neoplasia

1 reference

based on heuristic

inferred from title

adenocarcinoma in situ

1 reference

based on heuristic

inferred from title

author name string

Kevin A Ault

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Future II Study Group

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

1 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

369

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

9576

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1861-1868

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and other milestones for human papillomavirus vaccine introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exact estimates for a rate ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of adenocarcinoma in situ, micro-invasive, and early stage adenocarcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Model for assessing human papillomavirus vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960852-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)60852-6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40207173&oldid=1888723814"